Bioscience

Medivation Initiates Second Pivotal Phase 3 Trial Of Dimebon

June 23, 2008

By Flinn Foundation

[Source: Genome Web News] – Medivation, Inc. (NASDAQ: MDVN) announced it has initiated dosing of patients in its second pivotal Phase 3 trial of the investigational drug Dimebon